CN115803629A - 使用HIF-2α抑制剂和乐伐替尼的组合治疗癌症或VON-HIPPEL LINDAU病的方法 - Google Patents

使用HIF-2α抑制剂和乐伐替尼的组合治疗癌症或VON-HIPPEL LINDAU病的方法 Download PDF

Info

Publication number
CN115803629A
CN115803629A CN202180049537.5A CN202180049537A CN115803629A CN 115803629 A CN115803629 A CN 115803629A CN 202180049537 A CN202180049537 A CN 202180049537A CN 115803629 A CN115803629 A CN 115803629A
Authority
CN
China
Prior art keywords
rcc
cancer
lenvatinib
hif
human patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180049537.5A
Other languages
English (en)
Chinese (zh)
Inventor
R·F·佩里尼
E·M·皮涅罗
J·威尔曼罗杰里奥
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanitary Material R&d Management Co ltd
Merck Sharp and Dohme BV
Original Assignee
Sanitary Material R&d Management Co ltd
Merck Sharp and Dohme BV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanitary Material R&d Management Co ltd, Merck Sharp and Dohme BV filed Critical Sanitary Material R&d Management Co ltd
Publication of CN115803629A publication Critical patent/CN115803629A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
CN202180049537.5A 2020-06-22 2021-06-21 使用HIF-2α抑制剂和乐伐替尼的组合治疗癌症或VON-HIPPEL LINDAU病的方法 Pending CN115803629A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063042307P 2020-06-22 2020-06-22
US63/042307 2020-06-22
US202163146915P 2021-02-08 2021-02-08
US63/146915 2021-02-08
PCT/US2021/038172 WO2021262563A1 (en) 2020-06-22 2021-06-21 Methods for treating cancer or von-hippel lindau disease using a combination of a hif-2 alpha inhibitor and lenvatinib

Publications (1)

Publication Number Publication Date
CN115803629A true CN115803629A (zh) 2023-03-14

Family

ID=79281740

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180049537.5A Pending CN115803629A (zh) 2020-06-22 2021-06-21 使用HIF-2α抑制剂和乐伐替尼的组合治疗癌症或VON-HIPPEL LINDAU病的方法

Country Status (10)

Country Link
US (1) US20230210838A1 (https=)
EP (1) EP4168008B1 (https=)
JP (1) JP7750884B2 (https=)
KR (1) KR20230026493A (https=)
CN (1) CN115803629A (https=)
AU (1) AU2021296151A1 (https=)
BR (1) BR112022026094A2 (https=)
CA (1) CA3183852A1 (https=)
MX (2) MX2022016406A (https=)
WO (1) WO2021262563A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115463217B (zh) * 2021-06-11 2024-03-12 深圳埃格林医药有限公司 己酸羟孕酮在增强肿瘤治疗效果中的应用
CN119731864A (zh) 2023-02-28 2025-03-28 株式会社Lg新能源 电化学装置用分隔件和包括其的电化学装置
AU2024248799A1 (en) * 2023-03-31 2025-10-23 Daiichi Sankyo Company, Limited Combination of anti-CDH6 antibody-drug conjugate and HIF-2alpha inhibitor

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016168510A1 (en) * 2015-04-17 2016-10-20 Peloton Therapeutics, Inc. Combination therapy of a hif-2-alpha inhibitor and an immunotherapeutic agent and uses thereof
WO2018031680A1 (en) * 2016-08-10 2018-02-15 Fronthera U.S. Pharmaceuticals Llc Novel compounds, uses and methods for their preparation
WO2020081695A1 (en) * 2018-10-17 2020-04-23 Nikang Therapeutics, Inc. Indane derivatives as hypoxia inducible factor-2(alpha) inhibitors

Also Published As

Publication number Publication date
EP4168008A1 (en) 2023-04-26
JP7750884B2 (ja) 2025-10-07
JP2023531675A (ja) 2023-07-25
MX2025014865A (es) 2026-01-07
US20230210838A1 (en) 2023-07-06
EP4168008B1 (en) 2026-03-18
MX2022016406A (es) 2023-01-30
CA3183852A1 (en) 2021-12-30
EP4168008A4 (en) 2024-08-07
WO2021262563A1 (en) 2021-12-30
AU2021296151A1 (en) 2023-02-02
BR112022026094A2 (pt) 2023-01-17
KR20230026493A (ko) 2023-02-24

Similar Documents

Publication Publication Date Title
US20230181565A1 (en) Crenolanib combination therapy
CN104684579A (zh) 单特异性的和双特异性的抗-IGF-1R 和抗-ErbB3 抗体的剂量和施用
CN115845070A (zh) 用notch和pd-1或pd-l1抑制剂的组合治疗
Hedayat et al. Selumetinib: a selective MEK1 inhibitor for solid tumor treatment
RU2754452C2 (ru) Комбинированная терапия ингибиторами notch и pi3k/mtor для применения в лечении рака
CN107106685A (zh) 协同澳瑞他汀组合
CA3080644A1 (en) Use of parp inhibitor in treating chemotherapy-resistant ovarian cancer or breast cancer
EP4168008B1 (en) A combination of belzutifan and lenvatinib for use in treating cancer
JP2021502415A (ja) 癌の処置のためのアパチニブを用いる併用療法
WO2018170457A1 (en) Compositions, methods, systems and/or kits for preventing and/or treating neoplasms
JP2020506945A (ja) がんの治療のための方法、組成物及びキット
CN109069467B (zh) 肌生成抑制蛋白拮抗剂的用途、含有它们的组合及其用途
TWI771344B (zh) 一種ｖｅｇｆｒ抑制劑與ｐａｒｐ抑制劑聯合在製備治療胃癌的藥物中的用途
RU2858600C2 (ru) Способы лечения рака или болезни фон-гиппеля-линдау с использованием комбинации ингибитора hif-2 альфа и ленватиниба или его фармацевтически приемлемой соли
CN121311227A (zh) 用于治疗kras依赖性癌症的法尼基转移酶抑制剂
JP7308145B2 (ja) 固形腫瘍を治療するための医薬組成物
TW202308641A (zh) 用於治療癌症之方法及包含cdk抑制劑之給藥方案
JP7504106B2 (ja) がんの処置のための組合せ物
HK40087480A (zh) 使用HIF-2α抑制剂和乐伐替尼的组合治疗癌症或VON-HIPPEL LINDAU病的方法
WO2016161477A1 (en) A method of treating neoplasias
US20210113692A1 (en) Dosing regimen
RU2777519C2 (ru) Применение ингибитора parp в лечении резистентного к химиотерапии рака яичников или рака молочной железы
WO2024231875A1 (en) Hpk1 inhibitor for use in the treatment of cancer
JP2024531653A (ja) 固形腫瘍の処置のための経口投与パクリタキセル、Ｐ－ｇｐ阻害剤、およびチェックポイント阻害剤の治療的組み合わせ
Chen et al. Preclinical activity of the rational combination of apatinib in combination with CPT-11 in KRAS-mutant colorectal cancer patient-derived xenograft model

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40087480

Country of ref document: HK